FDA OKs expanded use of AbbVie’s Mavyret

he FDA approves an eight-week treatment cycle for AbbVie’s (ABBV +2.8%) Mavyret (glecaprevir and pibrentasvir) for treatment-naïve patients at least 12 years old or weighing at least 99 pounds who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection and compensated cirrhosis, the first eight-week treatment for this population. Previously, the standard length of therapy for these patients was 12 weeks or more.

https://seekingalpha.com/news/3502152-fda-oks-expanded-use-abbvies-mavyret